BUFFALO, N.Y., April 8, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) announced today the appointment of key clinical development and regulatory affairs executives to optimally position the company for successful development of its drug candidates. Jean Viallet, M.D., has joined the Company as Chief Development Officer, reporting to the Chief Executive Officer, and will be responsible for overseeing CBLI's clinical strategy, trials and operations, regulatory affairs and preclinical development. The Company also announced the appointment of Gillian Miller, Ph.D., as Senior Director of Regulatory Affairs and Judith Schnyder, MBA as Director of Clinical Operations.
Dr. Viallet brings more than 20 years of experience as a medical oncologist and senior executive at both large and small pharmaceutical companies. Most recently, Dr. Viallet established Viallet Oncology Consulting, LLC after serving as the Chief Medical Officer of Precision Therapeutics, Inc. Prior to this he guided clinical and preclinical development at Gemin X Pharmaceuticals, Inc., as their Executive Vice President and Chief Medical Officer, culminating in a successful strategic acquisition of Gemin X by Cephalon, Inc. Before joining Gemin X, Dr. Viallet held senior clinical oncology development positions at GlaxoSmithKline PLC and Sanofi. He has extensive experience with all phases of drug development and has been involved in multiple successful Investigational New Drug applications, New Drug Applications, Biologics License Applications, European Medicines Agency submissions and U.S. Food and Drug Administration Advisory Committees. Dr. Viallet has also served in several clinical and academic posts at Hospital Notre Dame, Montreal General Hospital, McGill University and the Universite de Montreal.
Dr. Viallet noted, "As a clinical oncologist and scientist, I am grateful for the opportunity to guide CBLI's drug candidates derived from world-class science into established therapeutic advances for cancer patients and victims of potentially lethal radiation exposure. The company's spirit of innovation, their commitment to developing breakthrough treatments for oncology and acute radiation syndrome and the promising 'trial-ready' drugs in their pipeline are what attracted me to CBLI."